{
    "2021-06-15": [
        [
            {
                "time": "",
                "original_text": "凯莱英：董事及高管拟减持不超过13.73万股 拟减持股份",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "董事",
                        "高管",
                        "减持",
                        "股份"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "凯莱英(002821.SZ)：部分董事及高管拟合计减持不超13.727万股 拟减持股份",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "董事",
                        "高管",
                        "减持",
                        "股份"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "凯莱英(002821.SZ)董事张达等拟合计减持不超13.73万股 拟减持股份",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "董事",
                        "张达",
                        "减持",
                        "股份"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "凯莱英：部分高级管理人员计划减持公司股份不超过13.7万股 拟减持股份",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "高级管理人员",
                        "减持",
                        "股份"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "注意！凯莱英：股东计划减持公司股份不超过约14万股 拟减持股份",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "股东",
                        "减持",
                        "股份"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "粤开医药行业周报 | 国家护航基因治疗产品，坚守医药创新逻辑主线",
                "features": {
                    "keywords": [
                        "医药",
                        "基因治疗",
                        "创新",
                        "逻辑主线"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "生物医药行业周报：国家医保药品目录调整常态化 助力创新药快速放量",
                "features": {
                    "keywords": [
                        "生物医药",
                        "医保",
                        "药品目录",
                        "创新药",
                        "放量"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "太平洋-医药行业周报：重点推荐丽珠集团和我武生物【行业研究】",
                "features": {
                    "keywords": [
                        "医药",
                        "丽珠集团",
                        "我武生物",
                        "推荐"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "每日理财观察：7万亿理财市场重磅新规落地",
                "features": {
                    "keywords": [
                        "理财",
                        "市场",
                        "新规",
                        "落地"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药行业2021年6月投资月报：6月仍然是较好的窗口期 两条思路配置医药",
                "features": {
                    "keywords": [
                        "医药",
                        "投资",
                        "窗口期",
                        "配置"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}